MAZE THERAPEUTICS INC (MAZE)

What MAZE THERAPEUTICS INC does

Maze Therapeutics is a clinical-stage biopharmaceutical company that uses human genetics data and proprietary target discovery platform called Compass to identify new therapeutic targets and advance them into clinical development. The company focuses on validating therapeutic targets across multiple disease indications and developing drug candidates such as MZE829 and MZE782. Maze operates by combining genomic insights with clinical development to address large addressable markets in therapeutic areas where unmet medical needs exist.

Fundamentals

• Price$32.42 as of 2026-07-09 close
• Market cap$1.8B as of 2026-07-10
• 1-year return+112.4% as of 2026-07-09 close
• Net margin+11.0% as of 2026-07-10
• ROE-36.6% as of 2026-07-10
• Debt / equity0.11 as of 2026-07-10
• Beta0.91 as of 2026-07-10

Ask why MAZE looks like this →

Key risks (from latest filing)

["Clinical trial timing and regulatory approval risks: The company's success depends on timely initiation and completion of preclinical studies and clinical trials for MZE829, MZE782, and other candidates, as well as obtaining and maintaining regulatory approvals, which are uncertain and costly.","Dependence on third-party relationships and human genetics data: Maze relies on third-party CROs, CMOs, suppliers and manufacturers, and on maintaining access to human genetics data, which could be disrupted or limited, impacting its ability to develop and validate therapeutic targets.","Competitive and regulatory landscape: The company operates in a competitive and rapidly changing environment with extensive government regulations in the US and foreign countries, and faces risks from existing competitors and new market entrants that could impact its ability to compete effectively and achieve market acceptance of therapeutic candidates."]

See MAZE's biggest risks from its latest 10-Q →